Topic: Health

Researchers found a sharp increase in poison control calls after semaglutide was approved for weight loss. The team analyzed data from 2012 to 2023 and discovered that most cases involved accidental dosing or therapeutic mistakes, not intentional misuse.

The FDA approved semaglutide (Ozempic and Wegovy) in 2021 for chronic weight management. But soon after, researchers noticed a dramatic increase in calls to poison control centers across the United States. Jordan Miller, an undergraduate student at UT San Antonio, wanted to find out if this surge was connected to the FDA's approval or just coincidental.

Miller worked with her research mentor David Han and other experts to analyze national poison control data. They found that before 2021, poison centers handled between 1,000 and 1,500 GLP-1RA related cases each year. But after mid-2021, this number nearly doubled, reaching over 8,000 by 2023.

The team's analysis showed that the FDA's approval of semaglutide for weight management marked a clear turning point. The number and type of poison control calls changed significantly after approval, reflecting the rapid expansion of semaglutide use beyond people with diabetes to a much larger population seeking weight loss.

Why It Matters

This study is important because it highlights the potential risks of misusing medications for weight loss. In India, where obesity rates are rising, this finding can help healthcare professionals and policymakers take steps to prevent similar issues.

Key Facts

• The FDA approved semaglutide (Ozempic and Wegovy) in 2021 for chronic weight management.
• There was a sharp increase in poison control calls after semaglutide's approval, with over 8,000 GLP-1RA related cases by 2023.
• Most cases involved accidental dosing or therapeutic mistakes, not intentional misuse.
• The FDA's approval of semaglutide for weight management marked a clear turning point in poison control calls.
• Semaglutide predominated post-approval (64.2%) with a significant inflection in call volume after approval.

Key Terms

GLP-1RA

Glucagon-like peptide-1 receptor agonists, medications for type 2 diabetes and weight loss

Poison control centers

Centers that handle calls about potential poisonings or overdoses

Implications

This study is important because it highlights the potential risks of misusing medications for weight loss. In India, where obesity rates are rising, this finding can help healthcare professionals and policymakers take steps to prevent similar issues.